Hefei Hanke Maibo Biotechnology

Hanke Maibo is a clinical-stage biopharmaceutical company based in Hefei, China, specializing in the development of next-generation cancer immunotherapies. The company focuses on monoclonal and bispecific antibodies, leveraging its proprietary technology platforms to target immune checkpoints and tumor-associated antigens. Its lead programs include HK010, a PD-L1/4-1BB bispecific antibody, and HK001, a PD-L1 inhibitor, both aimed at treating various solid tumors. Hanke Maibo aims to provide innovative and affordable biological drugs to address unmet medical needs in oncology. The company maintains a GMP-compliant manufacturing facility to support its clinical pipeline and future commercialization efforts.